Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma

Figures & data

Table 1 Patients characteristics

Characteristics	Number of patients (n=78)	%
Age (years)	Median 47 (range, 31–68)
Sex
Female	29	37.2
Male	49	62.8
ECOG performance status
0	21	26.9
1	45	57.7
2	12	15.4
WHO histology type
Type III	78	100
Tumor-involved site
Nasopharyngeal	4	5.1
Lymph node	10	12.8
Lungs	42	53.8
Liver	31	39.7
Bone	9	11.5
Relapse pattern
Recurrent	6	7.7
Metastatic	64	82.0
Recurrent and metastatic	8	10.3
Number of involved site
1	53	67.9
2	19	24.4
3	6	7.7
Initial received treatment (cases)
Treatment-naive	12	15.4
Radiation	66	84.6
Induction/concurrent/adjuvant chemotherapy	38	48.7

Abbreviations: ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization.

Figure 1 Kaplan–Meier curve of progression-free survival.

Figure 2 Kaplan–Meier curve of overall survival.

Table 2 Treatment-related adverse events (n=78)

Adverse events	NCI-CTC grade (% of patients)
	Grade 1	Grade 2	Grade 3	Grade 4
Hematological
Leucopenia	36 (46.2)	30 (38.5)	9 (11.5)	3 (3.8)
Anemia	27 (34.6)	18 (23.1)	6 (7.7)	0 (0.0)
Thrombocytopenia	29 (37.2)	12 (15.4)	0 (0.0)	0 (0.0)
Non-hematological
Nausea	41 (52.5)	23 (29.5)	0 (0.0)	0 (0.0)
Vomiting	38 (48.7)	17 (21.8)	0 (0.0)	0 (0.0)
Fatigue	22 (28.2)	14 (17.9)	0 (0.0)	0 (0.0)
Neuropathy	13 (16.7)	8 (10.3)	0 (0.0)	0 (0.0)
Neutropenia fever	0 (0.0)	3 (3.8)	0 (0.0)	0 (0.0)

Abbreviation: NCI-CTC, National Cancer Institute Common Toxicity Criteria.